Verve Therapeutics reports Q1 2024 net loss of $48.7M; cash runway to late 2026; VERVE-102 first patient dosed

Verve Therapeutics, Inc.

2024-Q1 EPS reported -$0.59

Net loss of $48.7M ($0.59 per share) vs $52.0M in Q1 2023; R&D expenses $48.4M.
Cash, cash equivalents, and marketable securities $606.4M; cash runway into late 2026.
First patient dosed in Heart-2 Phase 1b trial of VERVE-102 (PCSK9); data update expected 2025.
VERVE-201 (ANGPTL3) Phase 1b initiation on track for H2 2024; completed preclinical studies.
Received first milestone payment from Eli Lilly for Lp(a) collaboration; total potential milestones up to $465M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Verve Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, Verve Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-055063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.